Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: N/E PATSFAN who wrote (589)	1/28/2000 12:04:00 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 52153

NEPF.... the abstract that follows is lost on me, other than it sounds like (1) innovative chemistry, and (2) it would be toxic as heck. However, these guys are serious, serious chemists, and it looks like they've had their sites set on fungal and parasitic diseases for a long time. You should bounce their names off of tommysdad or Miljenko Zuanic. I have a long-standing interest in C-reactive protein, so I'll be watching for more. No, not a "stupid" or "another stupid" at all..... these guys are not coming out of the classical funding funnel for biotech, to my knowledge..... I've seen the name, but all of this stuff is new to me. Market cap shows that they already command some respect, be careful. Thanks! Proc Natl Acad Sci U S A 2000 Jan 4;97(1):12-6 Specific molecular recognition of mixed nucleic acid sequences: An aromatic dication that binds in the DNA minor groove as a dimer. Wang L, Bailly C, Kumar A, Ding D, Bajic M, Boykin DW, Wilson WD Department of Chemistry, Georgia State University, Atlanta, GA 30303, USA. [Medline record in process] Phenylamidine cationic groups linked by a furan ring (furamidine) and related compounds bind as monomers to AT sequences of DNA. An unsymmetric derivative (DB293) with one of the phenyl rings of furamidine replaced with a benzimidazole has been found by quantitative footprinting analyses to bind to GC-containing sites on DNA more strongly than to pure AT sequences. NMR structural analysis and surface plasmon resonance binding results clearly demonstrate that DB293 binds in the minor groove at specific GC-containing sequences of DNA in a highly cooperative manner as a stacked dimer. Neither the symmetric bisphenyl nor bisbenzimidazole analogs of DB293 bind significantly to the GC containing sequences. DB293 provides a paradigm for design of compounds for specific recognition of mixed DNA sequences and extends the boundaries for small molecule-DNA recognition.